Johnson & Johnson (NYSE:JNJ) VP Peter Fasolo sold 166,695 shares of Johnson & Johnson stock in a transaction on Tuesday, December 4th. The shares were sold at an average price of $146.41, for a total value of $24,405,814.95. Following the sale, the vice president now directly owns 155,540 shares in the company, valued at approximately $22,772,611.40. The sale was disclosed in a legal filing with the SEC, which is available through this link.

JNJ opened at $145.43 on Friday. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72. The firm has a market capitalization of $391.78 billion, a PE ratio of 19.92, a PEG ratio of 2.28 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The company had revenue of $20.35 billion for the quarter, compared to the consensus estimate of $20.05 billion. During the same quarter in the previous year, the business earned $1.90 EPS. The company’s quarterly revenue was up 3.6% compared to the same quarter last year. On average, research analysts forecast that Johnson & Johnson will post 8.16 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th will be paid a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.48%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s dividend payout ratio is presently 49.32%.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Raymond James Financial Services Advisors Inc. raised its position in shares of Johnson & Johnson by 3.5% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 1,123,184 shares of the company’s stock worth $136,289,000 after purchasing an additional 38,285 shares during the period. Sather Financial Group Inc raised its position in shares of Johnson & Johnson by 3.7% during the second quarter. Sather Financial Group Inc now owns 11,051 shares of the company’s stock worth $1,341,000 after purchasing an additional 399 shares during the period. Concentric Wealth Management LLC raised its position in shares of Johnson & Johnson by 3.2% during the second quarter. Concentric Wealth Management LLC now owns 26,611 shares of the company’s stock worth $3,229,000 after purchasing an additional 813 shares during the period. Narwhal Capital Management grew its holdings in shares of Johnson & Johnson by 2.5% during the second quarter. Narwhal Capital Management now owns 40,917 shares of the company’s stock valued at $4,965,000 after buying an additional 1,010 shares in the last quarter. Finally, Cardinal Capital Management grew its holdings in shares of Johnson & Johnson by 10.6% during the second quarter. Cardinal Capital Management now owns 101,715 shares of the company’s stock valued at $12,342,000 after buying an additional 9,767 shares in the last quarter. 66.51% of the stock is currently owned by institutional investors.

JNJ has been the topic of several recent analyst reports. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, November 27th. Wells Fargo & Co reaffirmed an “outperform” rating and set a $160.00 target price (up previously from $155.00) on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Credit Suisse Group lifted their target price on Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a research note on Wednesday, October 17th. Citigroup lifted their target price on Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a research note on Monday, October 22nd. Finally, Raymond James lifted their target price on Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research note on Wednesday, October 17th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $143.90.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.dailypolitical.com/2018/12/08/peter-fasolo-sells-166695-shares-of-johnson-johnson-jnj-stock.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Story: What are the reasons investors use put options?

Insider Buying and Selling by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.